Gene Weaver
Developer of a naturally derived, programmable enzymatic platform for controlled cutting and precision insertion of large genetic payloads. Focus areas include engineering specificity and programmability of recognition elements, enabling large-fragment DNA insertion and methods intended for use in mammalian cells. Cambridge-based, founded mid-2023.
Industries
Nr. of Employees
small (1-50)
Gene Weaver
Suite 9, Science Village, Chesterford Research Park, Little Chesterford, Essex CB10 1XL
Products
Programmable gene insertion platform (naturally derived enzymatic system)
A platform based on a naturally occurring enzymatic system engineered for programmable recognition, controlled cutting, and precision insertion of large genetic payloads.
Programmable gene insertion platform (naturally derived enzymatic system)
A platform based on a naturally occurring enzymatic system engineered for programmable recognition, controlled cutting, and precision insertion of large genetic payloads.
Services
Partnership-based collaborations to integrate intracellular delivery methods with programmable gene insertion technology, including development of optimized delivery workflows.
Partnership-based collaborations to integrate intracellular delivery methods with programmable gene insertion technology, including development of optimized delivery workflows.
Expertise Areas
- Programmable gene insertion
- Enzymatic gene editing
- Large-fragment DNA insertion
- Assay development for nucleic acid recombination
Key Technologies
- Programmable enzymatic insertion platform
- Large-fragment DNA insertion
- Non-DSB insertion methods
- In vitro recombination assays
News & Updates
Strategic collaboration to integrate an intracellular delivery platform with a programmable gene insertion technology for optimized delivery of multi-component cargos in mammalian cells.
Award of $515,214 from the Gates Foundation to investigate programmable gene insertion activity in mammalian cells and advance the platform for gene therapy applications.
Strategic collaboration to integrate an intracellular delivery platform with a programmable gene insertion technology for optimized delivery of multi-component cargos in mammalian cells.
Award of $515,214 from the Gates Foundation to investigate programmable gene insertion activity in mammalian cells and advance the platform for gene therapy applications.